In 89 migraine patients, fremanezumab reduced headache days significantly, with treatment-naive patients and certain clinical profiles predicting better response.
89 patientsProspective real-world cohort with response predictor analysis for fremanezumab
What the researchers found
Fremanezumab significantly reduced headache days in 89 patients, with treatment-naive status among the factors predicting better response.
Why it matters
With multiple CGRP antibodies available, knowing which patients respond best to fremanezumab helps personalize migraine prevention.
The numbers in context
N=89; headache days dropped from 21.1 to 12.4 per quarter; 61.8% achieved >=50% response; 6/10 erenumab non-responders responded to fremanezumab.
How the study worked
Prospective observational study tracking headache days one quarter before and after fremanezumab initiation in 89 patients.
Who was studied
Adults with high-frequency episodic or chronic migraine at a Spanish hospital (86.5% female, mean age 45.8)
What this study cannot tell us
Single-center observational study with relatively short follow-up (one quarter). No control group.
How to read the evidence
Prospective observational study — better than retrospective but lacks randomization and control group.
When this study was published
Published in 2025, reflecting current real-world prescribing patterns for the third available CGRP antibody.
The bigger picture
Real-world response predictor data helps move migraine treatment from trial-and-error toward personalized medicine.
Questions still open
- Do response predictors differ between fremanezumab and other CGRP antibodies?
- Do benefits increase or plateau with longer treatment duration?
Common questions
How effective is fremanezumab in the real world?
Who is most likely to respond to fremanezumab?
Read the original research
Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response.
Journal of clinical medicine, 14(4)
Citation
Polanco, Marcos; Gárate, Gabriel; Sánchez-Gudín, Julia; Madera, Jorge; Pascual, Julio; González-Quintanilla, Vicente. (2025). Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response.. Journal of clinical medicine, 14(4). https://doi.org/10.3390/jcm14041054